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ABSTRACT
We are currently experiencing an explosive growth in data collection technology that
threatens to dwarf the commensurate gains in computational power predicted by Moore’s
Law. At the same time, researchers across numerous domain sciences are finding success
using network models to represent their data. Graph algorithms are then applied to study
the topological structure and tease out latent relationships between variables.
Unfortunately, the problems of interest, such as finding dense subgraphs, are often the
most difficult to solve from a computational point of view. Together, these issues
motivate the need for novel algorithmic techniques in the study of graphs derived from
large, complex, data sources. This dissertation describes the development and application
of graph theoretic tools for the study of complex networks. Algorithms are presented that
leverage efficient, exact solutions to difficult combinatorial problems for epigenetic
biomarker detection and disease subtyping based on gene expression signatures.
Extensive testing on publicly available data is presented supporting the efficacy of these
approaches. To address efficient algorithm design, a study of the two core tenets of fixed
parameter tractability (branching and kernelization) is considered in the context of a
parallel implementation of vertex cover. Results of testing on a wide variety of graphs
derived from both real and synthetic data are presented. It is shown that the relative
success of kernelization versus branching is found to be largely dependent on the degree
distribution of the graph. Throughout, an emphasis is placed upon the practicality of
resulting implementations to advance the limits of effective computation.
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CHAPTER ONE INTRODUCTION AND BACKGROUND

Recent years have witnessed an explosive growth in the amount of raw data available for
researchers. Access to such vast stores of data provides exciting opportunities for new
discovery, while the very size of the datasets of interest creates ever evolving
computational challenges. Even though growth in computing power has continued to
observe Moore’s Law and double roughly every two years, the gains are being offset, and
in many cases dwarfed, by a corresponding growth in data size. In fact, it was estimated
in 2013 that 90% of the data available in the world had been generated in the two
preceding years alone [1].

At the same time, the study of complex networks such as biological, transportation,
social, and communication networks has become ubiquitous across the domain sciences.
For example, network models have been used in the elucidation of putative gene
networks [2, 3], the study of protein-protein interactions [4], examining the spread of
influence through social networks [5], and studying the organization of the human brain
[6]. Central to the understanding of such networks are their topological structures. As
such, the study of complex networks is intimately interwoven with graph theory and
graph algorithms.

In the study of complex networks, we must deal with two distinct hurdles. First, we are
faced with the ever-increasing rate of growth of available data sets. The second, and
perhaps more insidious challenge, is that the problems we often wish to solve are among
the most difficult from a computational point of view. For example, the problem of
finding the maximum clique in a graph, its largest fully connected subgraph, is in fact
NP-complete. Overcoming these difficulties will require the use of novel algorithmic
techniques such as Fixed Parameter Tractability (FPT) and the development of scalable
parallel solutions.
1

The primary focus of this dissertation is the development of novel graph-theoretical
approaches utilizing exact solutions for classical NP-complete problems to analyze the
structure of complex networks. The specific settings considered in chapters two and three
are from the biological sciences, but the applications transfer easily to other domains. To
address the computational challenges the quest for such exact solutions impose, chapter
four investigates the relative importance of the two key components of a parallel FPT
implementation of vertex cover – kernelization and branching. Finally, chapter five
summarizes the results and main contributions, as well as suggesting some avenues for
further research.

Data Types
Gene Expression

The history of modern DNA microarrays traces back to the colony hybridization method
of Grunstein and Hogness in 1975 [7]. In the roughly four decades since, microarray
technologies have proven to play a central role in advancing biological research.
Microarrays measure gene expression levels using chips with a set of hybridization
probes designed to target and bond to a specific sequence of mRNA. The technology has
advanced to the point that platforms such as the Affymetrix Exon 1.0 ST array are
capable of exon level resolution of expression with approximately 1.4 million probesets
comprised of over 5 million individual probes. For an excellent review of the history,
types, and applications of DNA microarrays see [8].

Epigenetic Data

When the Human Genome Project undertook its mission to map the entire DNA sequence
of the human genome in 1990, it carried the hope of transforming our understanding of
2

biology. In 2001 it was even chronicled in an episode of NOVA on PBS entitled
“Cracking the Code of Life [9].” While certainly representing a great leap forward in our
fundamental knowledge of genetics, it has become clear since its completion in 2003 that
there are mechanisms at play in the actual expression of genes that go far beyond the
physical arrangement of the underlying genetic code. These discoveries have led to the
establishment of a new branch of research – epigenetics. This fledgling field was defined
in 1990 by Robin Holiday as “the study of the mechanisms of temporal and spatial
control of gene activity during the development of complex organisms [10].” In recent
years, however, there has been some disagreement over whether the definition of an
epigenetic trait should be limited to those that are heritable [11].

A variety of epigenetic mechanisms have been discovered. Two of the major classes of
epigenetic modifications are DNA methylation and histone modification.

DNA methylation generally occurs when a methyl group is added at the 5’ position of the
cytosine ring, transforming the cytosine to 5-methylcytosine. Usually this occurs at CpG
dinucleotides, although non-CpG methylation has been seen to occur more frequently in
specific contexts such as neural development and in embryonic stem cells [12]. The
process is believed to be regulated by DNA methyltransferases including DNMT1,
DMNT3a, and DMNT3b. DNMT1 works to maintain methylation patterns by
recognizing and copying them to the unmethylated daughter strands during DNA
replication. DNMT3a and DMNT3b are thought to be responsible for de novo
methylation events. Mutations in the DNMT3b gene have been found to be responsible
for ICF (Immunodeficiency, centromeric instability, facial anomalies) syndrome [13],
while mutations to any of DNMT1, DNMT3a, or DNMT3b have been found to be
embryonically lethal in mice [14, 15].

In humans, some 70% of CpG dinucleotides throughout the genome are methylated [16].
At the same time, there are genomic regions with a heavy concentration of CpG content
3

that can be found in the promoter regions of many genes. The cytosines in these CpG rich
regions, termed CpG islands, tend normally to be unmethylated with exceptions in the
context of the inactive X chromosome [17] and imprinted genes [18, 19]. Aberrant
methylation patterns have been found to play a role in many diseases. In particular, it has
been shown to play a dual role in many forms of cancer through both a pattern of global
hypomethylation, allowing aberrant overexpression and ensuing oncogenesis, together
with hypermethylation of CpG islands in the promoter regions of tumor suppressor genes,
leading to their silencing [20-22].

Histone acetylation occurs when an acetyl group is added to the NH3+ group on Lysine.
The process takes place at the N-terminal of histone tails. Acetylation and deacetylation
are generally catalyzed by histone acetyltransferase (HAT) or histone deacetylase
(HDAC) enzymes respectively. Acetylation acts to transform the overall positive charge
of the histone tail to neutral, weakening the binding of the nucleosomal components and
making the DNA more accessible to transcriptional agents. Thus, hyperacetylation is
positively correlated with actively transcribed genes.

The lysine and arginine residues of the histone tails can be methylated, but it is most
commonly observed on the lysine residues of the tails of H3 and H4. Lysine can be
mono-, di-, or trimethylated with a methyl group replacing a hydrogen of its NH3+
group. Arginine has a free NH2 and NH2+ group and can be mono- or dimethylated. A
demethylation of arginine can occur on a single group, or with an asymmetric
methylation of each group.

Although DNA methylation and histone modifications are perhaps the most studied and
well known epigenetic mechanisms, a vast amount of ongoing research is also being
invested in other post-translational modifications such as phosphorylation, ubiquitination,
and somoylation.

4

Other Amenable Data Types

While the applications we consider in the next two chapters are drawn from the biological
domain, our methods are based on abstract models. As such, they can be applied to
virtually any type of data that admits such a model. The only requirements are that there
must be some entities that can be represented by nodes and we must be able to calculate
some similarity metric between them. Data can be continuous like the biological data
already considered, or categorical. For example, other work at the Langston Lab has used
graph algorithms to examine categorical data from the health disparities domain [23].

Translation to Graphs
Creation of Graphs

In seeking to analyze vast networks, we model the interactions as a graph so that we can
apply graph algorithms to better our understanding of the latent relationships. Nodes can
then be used to represent entities of interest, be they genes in a gene network, proteins in
a protein-protein interaction network, locations in a transportation network, or people in a
social network. In order to model the relationships between the actors represented by the
nodes, we must have some concept of how to place edges between them. In some
contexts, this is as straightforward as connecting “related” nodes, such as placing edges
between nodes in a social network if the people they represent are acquaintances or
between nodes in a road network if the locations they represent are connected by a road.
In others, we need a more mathematical or technical idea of a similarity measure such as
correlation coefficients or Jaccard similarity.

In the context of gene expression networks, we often build graphs with nodes
representing individual genes. Pearson correlation coefficients are then calculated for
each pair of genes taken across the measures for each sample. An edge is then placed
5

connecting the nodes if the correlation level (in absolute value) exceeds some
thresholding value.

Thresholding

There are a variety of methods that can be employed to select a suitable threshold value
to use. Often times, we may use methods based on experimentation. For example, when
building graphs for a paraclique analysis as in [24, 25], we may build a series of graphs
that gradually reduce the threshold until we encounter an inflection point in the number
of paracliques produced. Another approach is to use the spectral method introduced in
[26], which uses the eigenstructure of the adjacency matrix.

Relevant Graph Theory and Algorithms
Notations

A graph is an abstract representation of a network consisting of a set of vertices and a set
of edges that connect pairs of vertices. Formally, a graph 𝐺𝐺(𝑉𝑉, 𝐸𝐸) consists of a vertex set
𝑉𝑉 and an edge set 𝐸𝐸 containing ordered pairs of vertices from 𝑉𝑉 such that (𝑢𝑢, 𝑣𝑣) ∈ 𝐸𝐸

indicates the presence of an edge between 𝑢𝑢 and 𝑣𝑣. A graph is said to be simple if it

contains no self-loops or multiple edges. That is to say, there is no vertex with an edge
back to itself, and there is at most one edge connecting any particular pair of vertices. A
graph can be weighted by adding weight properties to its vertices, its edges, or both. In
this dissertation, all graphs considered are simple, finite, undirected and unweighted
unless explicitly noted otherwise.

6

A pair of vertices 𝑢𝑢 and 𝑣𝑣 are said to be adjacent if (𝑢𝑢, 𝑣𝑣) ∈ 𝐸𝐸. The size, or order, of a

graph is taken to be its number of vertices, |𝑉𝑉|. The degree of a vertex 𝑣𝑣 is the number of

vertices to which 𝑣𝑣 is adjacent, or equivalently, the number of edges with 𝑣𝑣 as an

endpoint. The neighborhood of a vertex 𝑣𝑣 in 𝐺𝐺, denoted by 𝑁𝑁𝐺𝐺 (𝑣𝑣) or, when the graph is
clear in context simply by 𝑁𝑁(𝑣𝑣), is the set of vertices that are adjacent to 𝑣𝑣. A subgraph
of a graph 𝐺𝐺(𝑉𝑉, 𝐸𝐸) is a graph 𝐺𝐺 ′ (𝑉𝑉 ′ , 𝐸𝐸 ′ ) such that 𝑉𝑉′ ⊆ 𝑉𝑉 and 𝐸𝐸′ ⊆ 𝐸𝐸, with the

requirement that if (𝑢𝑢′, 𝑣𝑣′) ∈ 𝐸𝐸′ , both 𝑢𝑢′ and 𝑣𝑣′ belong to 𝑉𝑉′. A subset of vertices can be
used to identify a subgraph of 𝐺𝐺 called an induced subgraph. An induced subgraph

contains the inducing vertices as its vertex set, and all the edges between those vertices
that were present in 𝐺𝐺. The complement of a graph 𝐺𝐺, denoted 𝐺𝐺̅ , is formed by removing
the existing edges, and adding those that were not originally present. Examples of an
induced subgraph and the complement of a graph can be seen in figure 1.

Figure 1. Induced subgraphs and graph complements. Suppose 𝐺𝐺 is the graph shown in
(a). Then (b) is its subgraph induced by the set of vertices {1,3,4,6}, and (c) is 𝐺𝐺̅ , its
complement.
7

The Clique Problem and the Paraclique Algorithm

A clique in a graph is a fully connected subgraph. In other words, a clique is simply a
subgraph containing all of its possible edges. The usual notation for a clique with 𝑛𝑛
vertices is 𝐾𝐾𝑛𝑛 . An example of a 𝐾𝐾5 can be seen in figure 2.

The identification of cliques has found a wide variety of applications, from identifying
putative gene pathways [27] to detecting collusive trading patterns in the stock market
[28]. The maximum clique problem is one of the most studied in graph theory. The
decision version, simply deciding if a graph contains a clique of a given input size, is one
of the original 21 NP-complete problems listed in Karp’s seminal work [29].

In practice, focusing solely on searching for cliques often proves too stringent a
requirement. The presence of noise in real world data often leads to missing edges in our
graphs. As the loss of even a single edge destroys a clique, such noise results in a higher
than desirable number of false negatives when examining the data for signal.

Figure 2. 𝐾𝐾5 , a clique on 5 vertices.

8

In order to provide more robust resistance to the effects of noise, the paraclique algorithm
was introduced in [25]. The basic idea is that we start with a maximum clique and grow it
to a paraclique by successively adding in, or glomming onto, vertices that are adjacent to
all but some acceptable number of vertices present at the current stage. The number of
edges allowed to be missed at each iteration is governed by a constant called the glom
term. An example of a paraclique can be seen in figure 3.

The paraclique algorithm has proven to be highly effective, and shown to outperform
other popular clustering techniques in terms of density and ontological enrichment [30].
Although most of the work involving the algorithm has to this point focused on its
application, theoretical work can be found in [25, 31].

The Dominating Set Problem

We can speak of both edge-dominating and vertex-dominating sets for a graph G. In this
dissertation, by a dominating set, we will mean a vertex-dominating set, that is, a subset S
of the vertex set V such that for every v in V, either v is in S or at least one of its
neighbors is in S. In particular, we will be interested in a variant of Dominating Set,
namely Red-Blue Dominating Set, in which the nodes of a graph are colored either red or
blue and we seek the smallest set of red vertices that dominate all the blue vertices (or
vice versa). See figure 4 for an example.

Fixed Parameter Tractability
In the past few decades, fixed parameter tractability has emerged as a powerful approach
to the design and implementation of practical algorithms for solving problems once
9

Figure 3. An example of a paraclique. This example was produced with glom term g=2
from a maximum clique of size four {1,2,3,4} (a) and progressively adding vertices 5 (b),
6 (c), and 7 (d).
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Figure 4. An example of red-blue dominating set. A minimum red-blue dominating set is
formed by the set of vertices {1,4}. Note that any such set must contain vertex 4 as it is
the only one to cover vertex 6. The covering edges as highlighted for clarity.

deemed hopelessly intractable. The origins of FPT trace back at least to the foundational
work of Fellows and Langston in the area of well-quasi-orderings and nonconstructive
tools for proving polynomial time computability [32-34]. Around the same time,
Robertson and Seymour proved the graph minor theorem, showing that undirected graphs
are well-quasi-ordered under the graph minor relationship [35]. These results provided
the impetus for the establishment of a new area of research, which would be termed Fixed
Parameter Tractability, in the seminal work by Downey and Fellows [36].

One goal of FPT is to provide a more fine-grained approach to classifying the difficulty
of a problem than that taken in classical complexity theory. Not all NP-complete
problems are created equally after all, and perhaps even more importantly, some
“difficult” problems may be solved very quickly in practice if we are only interested in
solutions of a particular size. The central idea is that if there is some parameter k in the
problem that, when held fixed, will allow the problem to be solved in time with any
super-exponential dependence being only in k, then the problem is in the class FPT. In
other words, a problem is FPT if it can be solved in time 𝑂𝑂(𝑓𝑓(𝑘𝑘)𝑛𝑛𝑐𝑐 ) where n is the

problem size, k is an input parameter, and c is a constant independent of both k and n.

11

There are two core tenets to Fixed Parameter Tractability – kernelization and branching.
Kernelization refers to a process of reducing the problem size to a compute kernel whose
size depends only on the fixed parameter k. This reduction must also be doable in
polynomial time with regards to the problem size. In [37] it is shown that a problem
being kernelizable is in fact equivalent to it being FPT.

Once the problem has been reduced to a compute-intensive kernel, it remains to explore
the resulting reduced search space. Various branching techniques aim to explore this
space as efficiently as possible. Whereas kernelization techniques aim to reduce the
impact of the original problem size in algorithm runtimes, improved branching aims to
reduce the remaining, often exponential, dependence on the size of the parameter k.

12

CHAPTER TWO NOVEL ALGORITHMIC DEVELOPMENT:
EPIGENETIC BIOMARKER DISCOVERY

In this chapter, we investigate the use of a combination of statistical scoring methods
with a red-blue dominating set filter for the elucidation of novel methylation biomarkers.
Parts of the material in this section have appeared previously in preliminary form in
posters or in papers currently submitted for publication. These will be cited as such
wherever appropriate.

Introduction and Overview of Methods
Previous work in the Langston Lab has produced innovative graph-theoretical tools for
mining gene co-expression data for transcriptomic biomarkers. In this study, we
investigate extensions and applications of these tools to the analysis of differential DNA
methylation data. Sites are scored with a statistical metric that gauges their potential
effectiveness for separating case data from control. Results are then filtered using red
blue dominating set. Inter-sample scores are calculated for sites passing this filter using a
custom scoring function that, based on site quality, favors homogeneous case-case and
control-control pairs over case-control pairs. This general line of research can be traced
back to the seminal toolchain first employed in [39].

Site Merit Scores

To begin, each methylation site is assigned a merit score by means of the following
function:
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑖𝑖) = |𝜇𝜇𝑖𝑖 (𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) − 𝜇𝜇𝑖𝑖 (𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)| − 𝛼𝛼|𝜎𝜎𝑖𝑖 (𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) + 𝜎𝜎𝑖𝑖 (𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)|
13

Where 𝜇𝜇𝑖𝑖 and 𝜎𝜎𝑖𝑖 are the mean and standard deviations, respectively, of the indicated

sample group and 𝛼𝛼 is a constant used as a tuning factor with 0 < 𝛼𝛼 ≤ 1. We start with

𝛼𝛼 = 1 and adjust it downward as necessary until we are able to identify sites with
positive merit scores.

Inter-sample Discrimination Scores

Ultimately the goal is to be able to identify sites that are capable of providing a clean
separation between case and control. To that end, we next calculate inter-sample scores.
The score comparing sample 𝑖𝑖 and sample 𝑗𝑗 is assigned via:
∑ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑘𝑘) ∙ �1 − �𝑚𝑚𝑚𝑚𝑚𝑚ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦_𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑖𝑖𝑖𝑖 − 𝑚𝑚𝑚𝑚𝑚𝑚ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦_𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑗𝑗𝑗𝑗 ��.
This metric is designed in such a way so as to favor homogeneous over heterogeneous
sample pairs. Thus, case-case pairs and control-control matched pairs will tend to receive
higher scores than mismatched case-control pairs. Presented with an unknown sample,
the user can then compute its scores against the training set and classify it based on the
group to which it most closely aligns.

Dominating Set Filter

Our scoring function has the potential to return a large number of sites with positive merit
scores. In practice, we would like to be able to winnow these sites down to those with the
best potential as discriminatory markers. In such situations, we apply a filter based on
red-blue dominating set.
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We first construct a bipartite graph with sites as red vertices forming one partite set and
samples as blue vertices in the other. For each site, we calculate the p-value of its
observed methylation level for each sample. This p-value is calculated in the distribution
of the levels at that site across all the group samples of the same type, be it case or
control. A site is said to cover a sample and an edge is added between them in the graph
if the p-value is greater than .05. This culls from the tails of the distributions and leaves
us with observed methylation values that are in some sense “normal” for the sample
within its group at each site.

Unfortunately, a straight application of minimum dominating set might sacrifice sites
with high merit scores for those with lower discriminatory power based solely on the size
of the returned set. To guard against this, we begin with the top scoring site and
iteratively add the next highest scoring until the set built up forms a dominating set. We
then take a minimum set from among this collection.

In order to visualize the effectiveness of our reduced set in discriminating between case
and control samples, we examine the distribution of the inter-sample scores. Presented
with an unknown sample, we could then compute its scores against the training set and
classify it based on which group it most closely aligns. That is, if it scores highly against
case, with lower scores against control, it would be classified as case and vice-versa.

Application: Biomarker Discovery in Human Disease
Parts of this section have appeared in preliminary form in the following research poster:
“Methylation Biomarker Discovery in Age-Related Diseases”, Ronald D. Hagan, Michael
A. Langston, Keystone Symposia Conference on Epigenetic Aging and Aging Related
Diseases, May 1-May 5, 2016, Santa Fe, New Mexico.
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Age is the single greatest risk known for developing a host of diseases including cancer,
dementia and osteoarthritis. Recent research has shown that epigenetic mechanisms too
seem to play a key role in these afflictions. Aberrant DNA methylation patterns in
particular have been associated with nearly all forms of human cancer. These discoveries
provide a compelling impetus for the development of methods for the discovery of novel
methylation biomarkers capable of differentiating between healthy and diseased states.
Such markers could then potentially be used in screening and diagnosis, and as guides for
the selection of therapeutic targets for DNA-demethylating agents.

We applied our method to eight sets of publicly available data obtained from GEO, the
Gene Expression Omnibus. These sets were chosen to span a variety of diseases, have a
relatively large number of case and control samples, and to come from a common
platform. All the sets are from the Illumina Infinium HumanMethylation450 BeadChip
array, often referred to as the Illumina 450k methylation array. The data sets are
summarized in Table 1.

Osteoarthritis

According to the Arthritis Foundation, osteoarthritis is the most common chronic
condition of the joints. Sometimes called degenerative joint disease, it has no specific
cause, but is influenced by several factors including age, occupation, obesity, injury and
overuse. As well as having a known genetic component, several studies have been
conducted that point to epigenetic mechanisms such as DNA methylation [40, 41] and
histone modifications [42, 43]. The GEO series GSE63695 consists of methylation data
from chondrocyte DNA samples drawn from the hip cartilage of 23 patients with
osteoarthritis, knee cartilage of 73 osteoarthritis patients, and 21 hip samples from
healthy controls. For the purpose of this study, we discarded the data from the knee
cartilage in order to avoid possible confounding issues due to a mixture of tissue types.
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Table 1. An overview of our methylation datasets. All sets consist of publicly available
data obtained from GEO – the Gene Expression Omnibus.
GEO Series Number

Disease

Case Samples

Control Samples

GSE63695

Osteoarthritis

23

21

GSE66695

Breast Cancer

80

40

GSE54503

Liver Cancer

66

66

GSE61107

Schizophrenia

24

24

GSE52588

Down Syndrome

29

29

GSE40360

Multiple Sclerosis

28

19

GSE62003

Dementia in T2D

18

18

GSE75679

Sjogren’s Syndrome

24

24
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With α = 1, we identified 777 sites with positive merit scores for separation. The top

scoring sites mapped to the genes ALX4, ANK1, and ARNT2. Differential expression of,
or differential methylation in the promoter regions for, each of these genes has been
indicated in the literature as playing a role in the development of osteoarthritis [44-46].

Our dominating set filter identified a set of three methylation sites that covered all
samples. As seen in Figure 5, the homogeneous sample pairs clearly
cluster toward the high end of the inter-sample scores giving a nice separation and a
classifier built to train on the data using our three sites should perform rather well.

In order to verify our hypothesis, we used the Multi-layer Perceptron model available in
the scikit-learn python package to construct a fully connected artificial neural net with
three hidden layers as illustrated in Figure 6. Using our three sites as the feature set, we
then conduct five-fold cross validation testing on the data set. For this Osteoarthritis data,
we obtained a mean accuracy of 0.89 indicating that our selected sites are indeed
effective for the purpose of classification.

Breast Cancer

Breast cancer in women accounts for one in ten of all new cancers diagnosed worldwide
annually [47]. As with all cancers, DNA methylation is known to play a large role in its
progression. A host of studies have been undertaken in efforts to improve our
understanding of that relationship. For example, see [48-50]. Series GSE66695 consists
of methylation data drawn from 40 normal and 80 breast cancer tissue samples.

In the breast cancer data, our scoring metric produced 12,107 sites with positive merit
scores for 𝛼𝛼 = 1. The top scoring sites mapped to ZFP106, MXRA7, and the tumor

suppressor gene ST7. MXRA7 has been found to be differentially expressed in a number
18
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Figure 5. Distribution of Osteoarthritis inter-sample scores.
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Figure 6. A fully connected neural network with three inputs and three hidden layers. The
input layer consists of a set of neurons {x1, x2, x3} representing the input features. Each
neuron in the hidden layers applies a weighted linear transform, followed by a nonlinear
activation function to the values it receives and feeds the result forward through the
network. From the results of the final hidden layer, the output layer calculates a result
classifying the original input.
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of cancers [51]. We were able to uncover a dominating set consisting of five sites
separating the data. The distribution of inter-sample scores shows a near total separation
of the homogeneous and heterogeneous sample pairs, lending strong evidence to support
the utility of our five sites as biomarkers for breast cancer. See Figure 7.

Once again we went a step further, seeking to validate our method using an artificial
neural net. Using scikit-learn once again with the same configuration as for the
osteoarthritis data, we used the five sites identified by our dominating set reduction as
features and conducted five-fold cross validation. In this case, we achieved a mean
accuracy of 0.96, strongly supporting our conclusions and also providing good anecdotal
evidence that the better the visual separation in the distribution of inter-sample scores, the
better the performance of the identified sites as features for classification.
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Figure 7. Distribution of Breast Cancer inter-sample scores.
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Liver Cancer

The most common type of primary liver cancer is hepatocellular carcinoma or HCC. It
ranks as the fifth most common type of cancer globally and is responsible for the third
most deaths due to cancers. Despite its high global rankings, the distribution of cases is
strongly centred in sub-Saharan Africa and Eastern Asia with China accounting for more
than 50% of all cases worldwide [52]. GSE54503 is made up of methylation data drawn
from 66 pairs of hepatocellular carcinoma (HCC) liver tumors and adjacent non-tumor
tissues.
With 𝛼𝛼 = 1, our scoring produced a set of 30,576 methylation sites having positive merit

scores. Dominating set filtering produced a set of four probes covering all samples. These
sites map to the genes KCNQ2, C1orf70, GRASP, and PTPRN2. All four can be found in
the literature as being involved in HCC, see [53-55]. As can be seen in Figure 8, the
distribution of inter-sample scores again provides a nearly ideal separation between like
and mixed sample pairs.

HCC Liver Cancer
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normal-HCC tumor

100
0
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Figure 8. Distribution of HCC inter-sample scores.
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Schizophrenia

GSE61107 comes from a genome-wide methylation analysis of brain tissue in
schizophrenia patients [56]. It is made up of data drawn from frontal cortex post-mortem
tissue from 24 individuals diagnosed with schizophrenia and 24 controls. The tissue
samples themselves were provided by the Human Brain and Spinal Fluid Resource
Centre.
With 𝛼𝛼 = 1, only four sites were identified with positive merit scores. Three of these
sites mapped to TNRC6C, ZNF787, and HOXA13, while the fourth mapped to an
intragenic region on chromosome 6. HOXA13 appears repeatedly as a potential
biomarker for schizophrenia in the literature. See for example [57-59]. While the
separation we obtain in this case is not to the level observed with the cancer datasets, we
still observe a marked upshift in the distribution of homogeneous inter-sample scores as
can be seen in Figure 9.

Down Syndrome

GEO series GSE52588 arises from a study aiming to identify a DNA methylation
signature of Down Syndrome in whole blood cells [60]. Data comes from whole
peripheral blood samples taken from 29 subjects affected by Down Syndrome as well as
29 matched samples taken from healthy familial controls (either mothers or unaffected
siblings).

While the cause of Down Syndrome is established as a trisomy of chromosome 21, the
underlying mechanisms influencing the variety of physical and mental manifestations of
the phenotype are largely unknown. Perhaps unsurprisingly, recent research has begun to

22

Schizophrenia
70

Sample Pairs

60
50
40
normal-normal

30

scz-scz

20

scz-normal

10
0.024

0.024

0.023

0.023

0.022

0.022

0.021

0.021

0.020

0.020

0.019

0.019

0.019

0.018

0.018

0.017

0.017

0

Inter-Sample Scores

Figure 9. Distribution of Schizophrenia inter-sample scores.

show a strong link to global patterns of aberrant methylation [61]. It has even been
suggested that methylation biomarkers could form the basis for non-invasive prenatal
screening [62].
With 𝛼𝛼 = 1, we initially obtained 2897 sites with positive merit scores. Interestingly,
only 42 of these sites map to chromosome 21. As can be seen in figure 10, these sites
produce a perfect separation between like and unlike sample pairs.
Multiple Sclerosis

GSE40360 originated from a study seeking to identify differences in methylation patterns
in pathology-free regions of brain tissue in persons affected by multiple sclerosis [63].
Drawn from brain bank samples of normal appearing white matter dissected from the
frontal lobe, it consists of post-mortem samples from 28 multiple sclerosis patients as
well as 19 healthy controls. This particular set turned out to be quite dirty, with numerous
23
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Figure 10. Distribution of Down Syndrome inter-sample scores.

missing values. As such, an initial preprocessing step was required. We chose to discard
records for all probes missing entries for a sample, leaving us with data for 460,421
probes.

This is our first dataset that returned no positive scores for a tuning factor of 1. Reducing
to 𝛼𝛼 = 0.9, we obtained a set of seven sites with positive merit scores. As can be seen in

figure 11, we start to see a decreased separation in the distribution commiserate with the

need to lower 𝛼𝛼. Notice however, that the homogeneous sample pairs still produce scores
that fall primarily in the top third of the distribution.
Dementia in Type 2 Diabetes

Along with the primary challenges associated with their disease, those suffering from
Type 2 Diabetes are at elevated risks for a host of other maladies including Alzheimer’s
disease. GSE62003 is taken from a study looking for methylation signatures
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Figure 11. Distribution of Multiple Sclerosis inter-sample scores.

differentiating between risk for developing dementia in elderly T2D patients [64]. It
consists of data taken from peripheral blood samples drawn from 18 individuals with
T2D who developed pre-symptomatic dementia within 18 months of undergoing a
baseline assessment and 18 controls who maintained normal cognitive function. Samples
are matched based on age, sex and education.

Initially we were unable to produce sites with a positive merit score for separation.
Reducing the tuning factor to 𝛼𝛼 = 0.8 produced 14 such sites. A look at the distribution

of inter-sample scores in figure 12 again shows a pattern that, while providing a less ideal
separation than observed in some previous cases, clearly segregates the majority of
homogeneous sample pairs into the top third.
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Figure 12. Distribution of inter-sample scores for dementia in Type 2 Diabetes.

Sjogren’s Syndrome

Sjogren’s syndrome is a systemic autoimmune disorder that affects the entire body, but
generally presents initially by attacking the moisture producing glands of the eyes and
mouth. Among the many possible complications for those suffering from primary
Sjogren’s syndrome (pSS) is background chronic fatigue. In [65], the authors study
methylation patterns associated with such concurrent fatigue. The associated dataset,
GSE75679, consists of methylation data measured in whole blood samples from 24 pSS
patients with high fatigue and 24 identified as low fatigue.

Once again, the initial run identified no sites having positive merit scores. Dropping the
tuning factor to 𝛼𝛼 = 0.7 produced eight sites. As can be seen in figure 13, in this case we
observed a distinctive comingling of the homogeneous and heterogeneous inter-sample
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Figure 13. Distribution of inter-sample scores for chronic fatigue in Sjogren’s.

scores. This leads us to believe that methylation based biomarkers might not be feasible
for identification of susceptibility to chronic fatigue in Sjogren’s Syndrome, at least not
when drawn from peripheral whole blood.
Summary and Discussion

Ongoing research by the biological community has established that epigenetic
mechanisms play a central role in the development of a variety of human diseases,
including most known forms of cancer. In this study, we examined the extension of a
method previously developed for biomarker discovery in gene expression data to a
similar role for use with DNA methylation data. Using a combination of statistical
scoring functions and graph-theoretical based filtering methods, our methods identify a
set of methylation sites that are putatively best suited to distinguish between case and
control samples.
27

We applied our methods to eight publicly available data sets obtained from the Gene
Expression Omnibus that together represent a broad cross-section of human disease. Each
set consists of both case and associated control samples. Our results show that our
methods have great promise in successfully identifying sets of putative biomarkers.
Beyond visual validation via observable separations in the distributions of inter-sample
scores, we also tested two of our resultant sets for efficacy as feature sets in the
construction of artificial neural network models. These models show the capacity for a
high degree of fidelity. Using five-fold cross validation we obtained mean accuracies of
0.96 and 0.89 for models for breast cancer and osteoarthritis respectively.

Application: Obesity Related Biomarkers for Adipose Tissue
Differentiation
Most of this section has appeared previously in either a joint paper submitted for
publication: “Genome-wide DNA Methylation Analysis Reveals Loci that Distinguish
Different Types of Adipose Tissue in Obese Individuals”, Donia Macartney-Coxson,
Miles C. Benton, Ray Blick, Richard S. Stibs, Ronald D. Hagan, Michael A. Langston
or in preliminary form in the poster: “Adipose Tissue DNA Methylation Markers
Associated with Weight-loss and Tissue Specificity”, Donia Macartney-Coxson, Miles
Benton, Alice Johnstone, Richard Stubbs, Ronald D. Hagan, Michael A. Langston,
Keystone Symposia Conference on Epigenetic Programming and Inheritance, April 6 –
April 10, 2014, Boston, Massachusetts.

My contributions include running experiments, enhancing our biomarker toolchain,
preparing figures, and writing up the results.
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Background

In humans, white adipose tissue consists of two main types, subcutaneous and visceral
(including omentum), that are distributed throughout the body in distinct depots.
Mitochondria rich brown adipose tissue depots, on the other hand, were once thought to
be found only in early development. Recent studies, however, have found higher than
expected levels of such depots in adults [66-68]. White adipose tissue can also undergo a
process of ‘browning’ or ‘beiging’ [69, 70]. Each of these types of adipose tissues have
distinct structural and biochemical properties [71-73], and both body fat distribution and
function influence metabolic risk [74-81]. Various studies have been undertaken
investigating the different developmental origins of subcutaneous and visceral adipose
tissue based on gene expression [73, 82-84], with recent evidence suggesting a
mesothelial origin for visceral adipose [85]. In addition, studies have begun to focus on
the role of DNA methylation in the differentiation and development of the various types
of adipose tissue [86, 87].

My co-authors previously performed DNA methylation analyses of paired subcutaneous
and omental adipose from obese individuals undergoing gastric bypass, seeking to
identify within-tissue differences before and after significant weight-loss (defined as a
subject losing more than 27% of their initial weight) [88]. In the current study, we
compare methylation levels between subcutaneous adipose and omentum tissue in an
effort to identify methylation biomarkers suitable for differentiating between the tissue
types both before and after weight-loss.
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Identification of Tissue Differentiation Markers

Applying our tools to the pre-operative samples produced 4900 CpG sites, mapping to
2309 genes, with positive merit scores for separating adipose tissue types and passing
initial filtering. As can be seen in figure 14, the distribution of inter-sample scores using
all 4900 sites produces an appealing, but not quite complete, separation of the tissues. For
the post-operative group, we identified 8624 CpG sites, mapping to 4066 genes, such
sites having positive merit scores. Once again, the identified sites produce an attractive
separation of tissue types, see figure 15. Of the sites identified in the two groups of
samples, 1022 produced positive merit scores for separation at both time points (pre- and
post-operative).
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Figure 14. Distribution of inter-sample scores for pre-operative tissue differentiation
using all 4900 sites with positive merit scores. Here and in the following figures legends,
omental tissue is denoted Om while subcutaneous adipose tissue is denoted by Ab.
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Figure 15. Distribution of inter-sample scores for post-operative tissue differentiation
using all 8624 sites with positive merit scores

Our initial analysis considered all sites with positive merit scores. As an ideal biomarker
panel would include the fewest markers needed for clean separation between case and
control groups, we examined the discriminatory power of a reduced number of sites at
each time point. We found that using only the 10 highest ranked sites was sufficient to
obtain good separation between the tissue types for both the before and after weight-loss
groups, see figure 16 and 17, respectively. We then reduced to the top scoring site for
each group. While a single site did not perform as well in the pre-operative group, we
found that the top site provided full discriminatory power in the post-operative samples.
See figures 18 and 19. An overview of the ten highest ranked sites at each time point can
be seen in Table 2.

Validation of Tissue Differentiation Markers

We performed a technical validation of our observations using pyrosequencing of robust
tissue discriminators from each analysis, i.e. the top 10 ranking sites from the before
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Figure 16. Distribution of inter-sample scores for pre-operative tissue differentiation
using the ten sites with highest merit scores.
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Figure 17. Distribution of inter-sample scores for post-operative tissue differentiation
using the ten sites with highest merit scores.
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Figure 18. Distribution of inter-sample scores for pre-operative tissue differentiation
using the single site with the highest merit score.
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Figure 19. Distribution of inter-sample scores for post-operative tissue differentiation
using the single site with the highest merit score.
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Table 2. Top 10 CpG sites ranked by merit score.
Illumina
probe ID

Mean beta AB
(+/- standard
deviation)

Mean beta OM
(+/- standard
deviation)

UCSC
Gene Name

CpG site
chromosome
and position+

Before
weight-loss
analysis
cg02245004
cg03923561
cg22747076
cg09400037
cg24376776
cg11797364
cg17496661
cg09720701
cg02264990
cg01524853

0.12 (+/- 0.08)
0.45 (+/- 0.07)
0.42 (+/- 0.09
0.42 (+/- 0.06)
0.03 (+/- 0.01)
0.59 (+/- 0.1)
0.65 (+/- 0.08)
0.37 (+/- 0.05)
0.35 (+/- 0.06)
0.43 (+/- 0.05)

0.64 (+/- 0.11)
0.04 (+/- 0.02)
0.02 (+/- 0.02)
0.82 (+/- 0.07)
0.33 (+/- 0.03)
0.97 (+/- 0.02)
0.99 (+/- 0.01)
0.06 (+/- 0.01)
0.03 (+/- 0.02)
0.12 (+/- 0.03)

Intergenic
HOXC4
HOXC4
Intergenic
Intergenic
Intergenic
Intergenic
HOXC4
HOXC4
HOXC4

15:76634887
12:54447220
12:54447873
16:84822801
10:101297245
6:436969
5:3326343
12:54447283
12:54447243
12:54447807

After weightloss analysis
cg00838040
cg21917524
cg24145118
cg12984729
cg12437821
cg01184975
cg20291855
cg25365014
cg16297011
cg21982455

0.34 (+/- 0.07)
0.31 (+/- 0.07)
0.84 (+/- 0.07)
0.09 (+/- 0.03)
0.46 (+/- 0.04)
0.53 (+/- 0.05)
0.03 (+/- 0.03)
0.79 (+/- 0.05)
0.07 (+/- 0.04)
0.56 (+/- 0.04)

0.97 (+/- 0.03)
0.81 (+/- 0.04)
0.31 (+/- 0.16)
0.59 (+/- 0.16)
0.05 (+/- 0.09)
0.10 (+/- 0.11)
0.44 (+/- 0.11)
0.41 (+/- 0.05)
0.48 (+/- 0.11)
0.19 (+/- 0.07)

ATP2C2
Intergenic
Intergenic
ISL2
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic

16:84446919
11:74200334
10:2777041
15:76633817
12:114852027
12:114852091
4:13524143
5:2727713
4:13539023
5:2757976
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weight-loss and the top site from the after weight-loss analyses. This revealed an
excellent agreement between the two methylation assays; before weight-loss (R2 = 0.910.98, P = 1.2x10-15–8.3x10-25), and the single site after weight-loss (R2 = 0.97, P = 4.9 x
10-14).

Next, we sought to test the performance of our candidate biomarkers in additional,
independent samples. DNA was available for a further 15 individuals before weight-loss
and 13 of these 15 individuals after weight-loss. Principal component analysis (PCA)
revealed a strong agreement between the discovery and validation samples for the before
weight-loss comparison, with no significant variation observed between genders in the
validation samples as can be seen in figure 20.

Figure 20. PCA analysis of the top 10 CpG sites from the before weight-loss tissue
samples. Analysis was performed on pyrosequence data. Tissue type is indicated by OM
(omentum) and subcutaneous abdominal adipose (AB), with Dis indicating the discovery
and Val the validation samples.
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We were able to obtain publicly available Illumina 450K data for a number of adipose
samples. Samples accessible through MARMAL-AID [89] included samples from 6 lean
male individuals with both subcutaneous and omental adipose tissue collected ≤ 12h postmortem (GSE48472 [90]), 14 visceral adipose samples from severely obese men, 7 of
which had metabolic syndrome (GSE54776 [91]), as well as 6 paired subcutaneous
adipose and gluteal adipose samples from lean females (GSE47513 [86]). Illumina 450K
data was also available for 642 subcutaneous adipose samples from individuals with an
average BMI of 26.7 (and a standard deviation of 4.9) [92] from the MuTHER (multiple
tissue human expression resource) project [93]. In examining the methylation profile of
all 11 strong discriminators from the before and after weight-loss groups in these publicly
available datasets, we observed good agreement within a tissue type irrespective of
gender and/or obesity phenotype.

In general, omental samples showed a tighter distribution of methylation for a given
probe than the subcutaneous adipose samples, and for the majority of probes a strongly
hyper-methylated (mean methylation beta >0.8, cg00838040, cg17496661, cg17496661)
or hypo-methylated (mean methylation beta <0.2, cg09720701, cg02264990,
cg22747076, cg03923561, cg22747076) phenotype. Given that the biomarker analysis
was trained on data from subcutaneous and omental adipose it is interesting to note that
the samples of subcutaneous gluteal adipose tissue from lean females showed a
methylation profile similar to that of the subcutaneous abdominal adipose samples and
clearly distinct from the omental samples.

Summary and Discussion

In this study, we applied our methylation biomarker tools to isolate CpG sites capable of
differentiating between white adipose tissue in human subjects both before and after
undergoing gastric bypass surgery. We identified a large set of sites with positive merit
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scores that we filtered to reveal 10 CpG sites before weight-loss and a single site after
weight-loss that strongly separated the tissue types. Additional confidence in our results
is provided by an excellent overlap between the pyrosequence methylation profiles of the
11 CpG sites in the discovery and validation cohorts and from publicly available
subcutaneous and omental adipose Illumina 450K data from lean, overweight and obese
individuals.

While there is no clinical utility in a marker to differentiate subcutaneous and omental
adipose, this study provides further support for the potential of DNA methylation as a
biomarker. Combined with the promising results of our work with disease data described
in the previous section, we believe future work to translate our combinatorial approach to
the detection of clinically applicable DNA methylation biomarkers is warranted, and may
have particular merit for situations in which robust differentiators are still urgently
required. Furthermore, because epigenetic mechanisms are dynamic and as such
potentially reversible, these types of analyses may also highlight innovative new avenues
for clinical treatment. Such analyses should take account of practicability concerns such
as ease of sample/tissue collection, and whether there is a biological argument for
potential DNA methylation differences between sample groups.
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CHAPTER THREE NOVEL ALGORITHMIC DEVELOPMENT:
SUBTYPING

In this chapter, we turn to gene co-expression data and the development of a method
based on the paraclique algorithm to identify unknown subtypes in human disease. A
portion of the material in this section appear in [94]. My contributions to this paper
include algorithm development, data aggregation, and experimentation and document
preparation.

Introduction
The ability to identify disease subtypes accurately and efficiently is a central pursuit in
the drive to individualized medicine. In the case of cancer patients, knowledge of a
genetic propensity towards chemo-resistance or towards early response can be used to
tailor treatment to be more, or less, aggressive. Early responders, for example, might
require less aggressive treatment, mitigating the long-term risks of adverse effects of
radiation therapy or chemotherapy associated toxicity. For example, studies have
identified gene expression signatures for chemo-resistance in both acute myeloid
leukemia and breast cancer [95, 96].

While techniques grounded in graph theory have been used to great effect in the pursuit
of genetic biomarkers for human disease and the discovery of novel gene networks, little
work has been done in trying to extend such tools to subtyping. The existing research has
primarily centered on the use of basic statistical or machine learning clustering methods
such as k-means, latent variable models, or mixture models [97-99].

Clique-centric methods have often been used for the discovery and modeling of coherent
networks. Unfortunately, clique finders are inherently prone to high false negative rates.
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Indeed, an entire clique will be lost if even a single edge is missing. The paraclique
algorithm was introduced to address the difficulties presented by signal loss due to noise
in the data. While paracliques can be constructed in different ways, the basic idea is to
take a maximum clique as a core, then expand it to a paraclique by adding vertices
adjacent to all but some allowable number g of its vertices.

Here, we present a method for subtyping based on the paraclique algorithm. The
remainder of this chapter is organized as follows. An overview of our method and the
data sets initially used for experimentation are provided in the next section. We then
discuss the initial validation testing and examine additional steps taken to verify the
biological relevance of our results. Finally, we provide avenues for continued research.

Methods and Data
In an effort to limit the effects of confounding factors, we use an initial filtering step.
FDR corrected p-values for differential expression of genes between case and control sets
are calculated, and only those with p-values less than 0.1 are retained. The idea being that
this technique will limit our attention to those genes of interest only in the case group.
After all, we are not interested in subgroups based on age, ethnicity, or hair color. The pvalues are calculated using the EntropyExplorer R package [100]. After filtering, the data
tables are transposed and we calculate the pairwise Pearson correlation coefficients
between samples across the expression levels. Thresholding the correlation matrix, we
then create an unweighted graph with vertices representing individual samples and edges
between vertices if the corresponding samples are correlated above the thresholding level
(in absolute value). Once the graph is built, we run the paraclique algorithm to extract
dense subgraphs of patients representing putative subtypes in the case samples. Finally,
we separate the groups, return the tables to their original configuration, and calculate
differential expression across subtypes. Here, the level of differential expression is taken
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to be simply the difference in the mean expression levels between the groups. An
overview of our method can be found in Figure 21.

We initially applied or methods to 12 sets of publicly available gene expression data
obtained from the Gene Expression Omnibus (GEO). The data sets were selected to
provide a wide cross-section of human disease and to have information on both a case
and control group for initial filtering. Table 3 gives an overview of the datasets used.

Initial Validation and Discussion
Our investigation into the effectiveness of our proposed method was focused on two
guiding questions. First, is the method capable of reliably identifying putative subtypes?
Second, is there biological evidence confirming or at least supporting these subtypes as
being biologically relevant to the associated disease?

We found that the answer to the first question is unequivocally yes. As summarized in
Table 4, we found putative subtypes in 10 of our datasets. In the other two cases, we
hypothesize that our method fails due to limiting conditions present in the data. First, the
sizes of the datasets are relatively small (only 10 samples in both cases) and may not give
a true representation of the underlying populations. Secondly, the disease in question
might not have meaningful subtypes based on differential gene expression.

The second question is considerably more difficult to answer. In order to address it, we
followed a two-prong approach in examining the top differentially expressed genes
between subgroups. To begin, we calculated the GO enrichments of the top 100 genes
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Preprocessing

Graph Creation Metric: sample-sample
correlations

Paraclique Extraction

Putative Subgroups

Figure 21. Suptyping method overview. A greatly simplified view of our subtyping
workflow. Gene expression data is preprocessed with an initial filtering step. A graph is
created using the pairwise sample correlation scores taken across the expression scores.
Paracliques are then extracted that represent putative subtypes.
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Table 3. Subtyping datasets. An overview of the datasets used in this study.
Disease

GEO
Accession

Probes

Probes After
Filtering

Case

Control

Asthma

GSE4302

54675

2322

42

28

Breast Cancer

GSE10810

18382

11531

31

27

CLL

GSE8835

22283

1338

24

12

Colorectal Cancer

GSE9348

54675

22968

70

12

Lung Cancer

GSE7670

22283

7458

27

27

Multiple Sclerosis

GDS3920

54674

9844

14

15

Pancreatic Cancer

GDS4102

54613

23711

36

16

Parkinson’s

GSE20141

54674

6625

10

8

Prostate Cancer

GSE6919

12625

1531

61

63

Psoriasis

GSE13355

54675

29407

58

58

Schizophrenia

GSE17612

54675

4250

28

23

T2 Diabetes

GSE20966

61294

93

10

10
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Table 4. Subgroups identified. Summary of the number and sizes of putative subgroups
identified by our methods in the test data.
Disease

Number of Subgroups

Size of Subgroups

Identified

Identified

Asthma

2

32,8

Breast Cancer

2

22,5

CLL

2

4,18

Colorectal Cancer

2

63,5

Lung Cancer

2

21,5

Multiple Sclerosis

2

11,3

Pancreatic Cancer

2

31,5

Parkinson’s

1

8

Prostate Cancer

2

56,3

Psoriasis

2

49,5

Schizophrenia

2

19,6

T2 Diabetes

1

9
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and the associated enrichment p-value. The results, along with the associated enriched
GO categories, are summarized in Table 5. We next performed a literature search to
check the lists of the top genes for involvement in known subtypes. We were able to find
strong empirical evidence to support having successfully identified known groups in four
of our datasets: Asthma, Breast Cancer, CLL, and Colorectal Cancer. Before we go
further, let us look at these four cases in more detail.

Asthma

The incidence of asthma in the U.S has been on the rise for two decades. It is currently
estimated that 9.6% of children under 18 are asthmatic, with the risks for some groups
based on ethnicity (particularly African American and Puerto Rican) and stratification by
lower socioeconomic status rising as high as 16% [101].

The GEO series GSE4302 is derived from a study designed to identify genes associated
with response in asthmatics to treatment with corticosteroids [102]. It consists of
expression data derived from epithelial airway brushings taken from 42 asthmatics and a
control group consisting of 28 healthy subjects and 16 smokers. For our analysis, we used
only the healthy subjects as control, discarding the smokers. Data is derived from a
microarray analysis using the Affymetrix Human Genome U133 Plus 2.0 Array.

Our initial filtering step reduced the original 54,676 probes to a set of 2322 having FDR
corrected p-values < 0.1 for differential expression between the case and control groups.
With the reduced set of variables and a threshold of 0.93, our method produced three
putative subgroups of size 31,8, and 3. The 100 most differentially expressed genes
between the groups included CLCA1, periostin, and ovalbumin. All three of these genes
were reported in [103] to be markers of a Th2-high endotype of asthma.
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Table 5. GO enrichment. The GO term category with the lowest p-value for the
enrichment of the 100 most differentially expressed genes across identified subgroups.
Data Set

Category

p-value

Asthma GSE4302

Oxireductase

1.1E-4

Breast Cancer GSE10810

Secreted

1.0E-13

CLL GSE8835

Mhc ii

2.4E-15

Colorectal Cancer GSE9348

Translational elongation

2.8E-28

Lung Cancer GSE7670

Secreted

7.7E-10

Multiple Sclerosis GDS3920

Translational elongation

1.9E-34

Pancreatic Cancer GDS4102

Signal

4.59E-15

Prostate Cancer GSE6919

Translational elongation

4.92E-46

Psoriasis GSE13355

Immune response

3.5E-15

Schizophrenia GSE17612

Organelle membrane

5.24E-4
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Breast Cancer

Genetic factors have long been known to play a significant role in breast cancer. In
families that have had at least 4 cases of breast cancer, studies have shown the majority
of cases can be linked to mutations in either BRCA1 or BRCA2 genes [104, 105]. In
addition, breast cancer has a variety of known subtypes that significantly impact
prognosis and treatment. For example, tumors negative for estrogen receptors,
progesterone receptors, and the expression of HER2 are indicative of triple-negative
breast cancer, a subtype identified with higher risk of recurrence and 5-year mortality
[106].

GSE10810 comes from a study aiming to investigate more fully the links between gene
expression and phenotypic differences in breast cancer [107]. It consists of gene
expression data for 31 tumor samples and a control set of 27 healthy tissue samples. The
platform used for the study was again the Affymetrix Human Genome U133 Plus 2.0
Array, although only data for 18,382 probes was provided.

The number of probes was reduced to 11,531 with false discovery rate adjusted p-values
for differential expression between the case and control groups < 0.1. Using a threshold
of 0.8, our tools produced 2 putative subgroups of size 22 and 5. The 100 most
differentially expressed genes between these subgroups include SLC39A6, S100a4,
AGR3, Cd24, and epcam. All of these genes have been reported in the literature as being
markers for different phenotypes of breast cancer [108-112].

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is one of the most common types of leukemia
with pathogenesis presenting as an overproduction of neoplastic B cells in the
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bloodstream. The median age at diagnosis is 65, and more commonly affects males [113].
It typically presents with a slow progression, with patients living out a normal life
expectancy. In some cases, however, it can be aggressive, with death occurring less than
5 years after onset.

The dataset GSE8835 was provided by a study with the aim of examining the effects of
CLL on the expression levels in peripheral blood T cells [114]. It is made up of 24 CD4
cell samples from CLL patients and a control group of 12 CD4 cell samples from healthy,
age matched donors. The Affymetrix Human Genome U133A Array with 22,283 probes
was used.

Filtering reduced the initial probes to a set of 1338 having p-values less than 0.1 (again
FDR corrected). A threshold of 0.8 produced two subgroups of size 4 and 18. The most
differentially expressed genes across the two groups included ZAP-70, previously
identified as the best discriminator of Ig-mutated and Ig-unmutated CLL [115].

Colorectal Cancer

The incidence of colorectal cancer (CRC) has been in decline since the mid 1980’s [116].
Despite this significant drop in prevalence, it still annually accounts for both the third
highest number of new cases of cancer, and the third highest number of cancer deaths
[117]. As in breast cancer, there are known hereditary links to CRC. For example, a
mutation of the gene APC is responsible for two syndromes, Familial Adenomatous
Polyposis and Hereditary Nonpolyposis Colorectal Cancer, that each carry a significant
increase in the risk of developing CRC [118].

GSE9348 was derived from a study aiming to find a gene expression signature for cases
of early stage CRC that are prone to metastasis [119]. It consists of gene expression data
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derived from tumors of 70 patients and tissue from 12 healthy controls. The samples are
age and ethnicity matched. The study utilized the Affymetrix U133 Plus 2 array.

Our filtering reduced the 54675 probes in the original set to 22968 with FDR corrected pvalues < 0.1 for differential expression between the case and control groups. With a
threshold of 0.87, our tools produced two paracliques representing putative subgroups in
the tumor samples of size 63 and 5. The list of 100 genes most differentially expressed
between these two groups include Cd24, identified as a prognostic marker for CRC [120]
as well as OLFM4, indicated in as a marker for tumor differentiation and progression
[121, 122].

Further Validation: Testing with Known Subtypes
While our initial validation efforts indicate that our methods indeed have the potential to
identify both known and novel subtypes based on biologically relevant genetic signatures,
the lack of an established ground truth is a distinct limitation for our testing. In order to
address this point, we identified two additional sets of publicly available data on GEO
that included labeling for membership into distinct subtypes. The goal of course being to
apply our tools in a search for evidence that we could identify subgroups appropriately
stratifying the samples.

Gastric Cancer

The first set is GSE35809, consisting of gene expression data from 70 primary gastric
tumors used as a validation set for testing of a classifier for tumor subtypes [123-125].
The samples are identified in the data as belonging to one of three subtypes: proliferative,
invasive, or metabolic. The number of samples for each type in the original data are 29,
26, and 15 respectively.
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As this set does not contain accompanying control data, we forgo the initial filtering
phase. Applying the remainder of our toolchain and using a threshold of 0.955, we
identified two subgroups that, while both contained a mixture of metabolic tumors, nearly
perfectly segregated the invasive and proliferative types. See Table 6.

Non-Small Cell Lung Cancer

Non-small cell lung cancer, or NSCLC, has two major known subtypes –
adenocarcinoma (AC), and squamous cell carcinoma (SCC). GSE10245 is made up of
gene expression data for 40 adenocarcinoma, and 18 squamous cell carcinoma NSCLC
tumors and was provided from a study examining differential expression between the two
types [126].

Table 6. Known subtype results. A breakdown of the composition of the subtypes
obtained from the cases with included subtype labeling. In both cases, we obtained
putative subgraphs that cleanly segregated the samples according to subtype.
Gastric Cancer

NSCLC

Paraclique Sizes
29

Paraclique Sizes

16

Subtype

26

12

8

Subtype

proliferative

1

12

AC

23

0

8

invasive

19

1

SCC

3

12

0

metabolic

9

3
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Once again, the set lacks control data, so the initial filtering must be skipped. For this
dataset, our tools, with a threshold of 0.94, identifies 3 putative subgroups that show a
remarkable separation between the subtypes. Referring once again to Table 6, we see that
two of the three groups are completely homogeneous, while the third consists of 23 AC
tumors with a crossover of only 3 SCCs.

Subtyping Summary
In this chapter, we have described a method based on the paraclique algorithm to identify
putative subtypes separating samples based on signatures in their gene expression
profiles. We applied our methods to a variety of publicly available data starting with 12
sets obtained from the Gene Expression Omnibus. Of those 12, our tools identified
putative subtypes for 10. We sought to validate the relevance of our findings by
reviewing the literature and examining the GO enrichment for biological relevance of
genes differentially expressed across our potential subtypes. We also performed
additional testing with two sets data containing phenotypic information for known
subtypes, also obtained from GEO. The results of our testing indicate a strong potential
for our approach to be highly effective in the discovery of novel subtypes.
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CHAPTER FOUR CRITICAL ALGORITHMIC ANALYSIS:
KERNELIZATION VERSUS BRANCHING

Most of this chapter appeared previously in [127]. My contributions include
implementing the full degree 2 rule, collecting testbed graphs, running experiments and
writing the paper.

In this chapter, we investigate the relative significance of kernelization versus branching
for parallel FPT implementations. Using the well-known vertex cover problem as a
familiar example, we build and experiment with a testbed of five different classes of
difficult graphs. For some, we find that kernelization alone obviates the need for
parallelism. For others, we show that kernelization and branching work in synergy to
produce efficient implementations. And yet for others, kernelization fails completely,
leaving branching to solve the entire problem. Structural graph properties are studied in
an effort to explicate this trichotomy. The NP-completeness of vertex cover makes
scalability an extreme challenge.

Introduction
Fixed-Parameter Tractability (FPT) has become a popular and powerful technique for
dealing with the recalcitrance of NP-completeness. An amenable problem is FPT if it has
an algorithm that runs in O(f(k)nc) time, where n is the problem size, k is the input
parameter, and c is a constant independent of n and k. Representative citations include
[36] for theoretical development, [128] for previous work on parallel implementations,
and [129] for historical perspective.
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Vertex cover is probably the best known and most widely studied FPT problem. In its
usual decision formulation, we are given a simple undirected graph G of order n and an
integer k, and asked whether G contains a set S of at most k vertices so that every edge in
G has at least one endpoint in S. Minimum vertex cover and its complementary dual,
maximum clique, are highly appreciated for both their prominence in complexity theory
and their wealth of practical applications.

Two tenets of FPT are kernelization, in which an input of size n is reduced to a compute
core whose size depends only on k, and branching, whereby an efficient tree structure is
used to explore the solution space. It would not be a gross oversimplification to say that
kernelization is generally fast, while branching is not. That some part of the solution
process is slow and exhaustive should not come as a surprise. After all, we are trying to
solve enormous NP-complete problems exactly. On the other hand, the relative speed of
kernelization should not belie its importance. Only by reducing the problem size
dramatically can we hope for runtimes polynomial in n.

In recent work [130], it has been shown that one can often obtain excellent parallel
speedup on large-scale biological graphs, as primarily derived from transcriptomic data.
These sorts of graphs tend to be relatively sparse, more or less scale free, and contain
many highly overlapping cliques of various sizes. It was found that kernelization and
branching tend to work together quite well for these types of inputs. Methods were in fact
often interleaved [131].

In this chapter, we study these and other input domains in an effort to elucidate the
relative significance of kernelization versus branching and the need for parallel FPT
computation. To this end, we use reasonably straightforward sequential and parallel FPT
vertex cover implementations and examine performance on large graphs of five general
classes: physical infrastructure, social interaction, high-throughput biological, pseudorandom, and regularly structured. Despite their notoriety, we find that infrastructure and
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social graphs tend to succumb to mere kernelization. Biological graphs, meanwhile,
benefit from both kernelization and branching. On the other hand, regularly structured
and, to a lesser extent, pseudo-random graphs tend to be resistant to kernelization. Thus
they benefit from highly efficient branching, parallelized implementations and effective
load balancing strategies.

In the next two sections, we detail important relevant features of kernelization and
branching. Section 4 contains descriptions and discussions of the various sources and
sorts of domain data we use in this study. We also present sample timings for each. In
Sections 5 and 6 we analyze these results and discuss directions for future study.

Kernelization Rules
Let us briefly review standard vertex cover kernelization reductions. The easiest to apply
are the low degree rule, the high degree rule, and the degree two rule. It is noteworthy
that the high degree rule alone ensures an O(k2) kernel. Given G, n and k, we iteratively
apply these rules, at each stage creating a new graph G′ with n′ ≤ n and k′ ≤ k.
The Low Degree Rule: Any isolated vertex cannot cover any edges and may be
removed, reducing n′ by 1. In the case of a vertex of degree one, we can cover no fewer
edges by discarding it and removing its parent and putting it in the cover. This reduces n′
by 2 and k′ by 1.
The High Degree Rule: If a vertex has degree greater than k then it must be included in
an acceptable cover. Otherwise there would be at least k+1 edges, which could only be
covered by including all its neighbors. Removing such a vertex and putting it in the cover
reduces n′ by 1 and k′ by 1.
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The Degree Two Rule: This rule is considerably more complicated. There are two
separate cases to consider. Suppose u has degree two, with neighbors v and w.

Case 1: v and w are neighbors. In this case, at least two of u, v, and w must be included in
any satisfying cover in order to account for the edges of the triangle they form. Including
u would cover only two edges, while v and w both cover at least two and possibly more.
Thus, we are best served by removing all three vertices and including v and w in the
cover. This reduces n′ by 3 and k′ by 2.
Case 2: v and w are not neighbors. In this case, we form G′ by folding u, v, and w into a
new vertex, u′, whose neighborhood consists of the union of the other neighbors of v and
w. It turns out that G′ contains a vertex cover of size k′ = k – 1 if and only if G contains a
vertex cover of size k. See Figure 22 for an example. (For completeness, we note that
there are actually two options. If the cover of G′ contains u′, then v and w will be in the
cover for G while u may be discarded. If the cover of G′ does not contain u′, then u will
be in the cover for G while v and w may be discarded. With either option, n′ is reduced by
2 and k′ is reduced by 1. The specific option to choose is only relevant in backtracking,
when solving the search not the decision version of the problem.)

After applying these rules, we have reduced our original question of the existence of a
cover for G of size no more than k to the search for a cover of G′ of size less than or equal
to k′.
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Figure 22. Kernelization. An example of Case 2 of the degree two rule. Vertices u, v, and
w are folded into u′.

55

Branching Strategies
After kernelization, we are left with the computationally imposing task of exploring a
search space whose size is exponential in k. The best current theoretical running time can
be found in [132]. There, a limit of O(1.2738k + kn) is achieved, but at the cost of
excruciating branching techniques, some of which may actually work against us on
average. Thus, we employ instead a relatively simple search tree strategy to traverse the
possible covers. At each level in the tree, we choose the vertex, v, of highest degree and
branch in two directions. For the left branch, we add v to the candidate cover. For the
right branch, we discard v and place all of v’s neighbors in the cover. This
straightforward but easily parallelized technique is illustrated in Figure 23.

The search along each branch proceeds until either k vertices have been added to the
candidate solution or all edges are covered. At that point, the validity of the cover is
checked. If a satisfying cover has indeed been found, then all search paths are terminated
and we return a “yes” decision. On the other hand, if the candidate cover is not a
satisfying cover, then branching must continue until we find a solution or exhaust the
search space. At each branching stage, we include at least one more vertex in the
candidate solution. Thus, this process results in a search tree of depth bounded by k.
Kernelization times are generally insignificant. Branching tends to be exhaustive,
however, and so it is the usual focus for parallel FPT speedups.

Each branching path reduces graph size and complexity. It is therefore sometimes
possible to re-kernelize at branch points. We use this technique, known as interleaving
[133], in our implementations in an effort to reduce overall run times and enhance
parallel speedups.
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Figure 23. Branching. Dark vertices are placed into a candidate cover.

57

For parallel implementations, we perform search tree decomposition in MPI, using a
master-slave paradigm. Each processor is initially assigned an independent branch to
search. Without some form of load balancing, however, a processor may starve should it
finish its branch early. Thus, we employ dynamic load balancing to keep all processors
busy. Our approach designates a highest degree branch as a donor. When any branch
completes, it receives additional work from the donor. Should the donor itself terminate
early, a new donor is selected again based on highest degree. For a thorough description
of the approach and an analysis of its effectiveness, see [128, 130].

Data and Experiments
Large-scale experiments were conducted on DOE’s Hopper supercomputer, named after
the remarkable computing pioneer Admiral Grace Murray Hopper. Part of the National
Energy Research Scientific Computing (NERSC) Center, the Hopper platform was
ranked 16th fastest in the world according to the TOP500 list for June, 2012. It is a
CrayXE6 system rated at a peak speed of 1.28 PetaFLOPS, which it attains with 6,384
nodes made up of two 2.1 GHz twelve-core AMD ‘MagnyCours’ processors, for a total
of 153,216 compute cores. Hopper is maintained at the Lawrence Berkeley National
Laboratory.

We sought to test graphs from a broad variety of application domains. Our interest
focused on finding graphs that are enormous and/or difficult enough to pose a challenge,
even for our streamlined vertex cover FPT implementations. The graphs we selected fall
into five general categories: physical infrastructure, social interaction, high-throughput
biological, pseudo-random, and regularly structured. Three representative graphs were
selected from each class. For each such graph, we computed the minimum vertex cover in
the complement, and employed a simple binary search to determine the optimum
parameter value. To identify the hardest instances, we report timings for the largest “no”
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parameter value. (Had we used instead the smallest “yes” value, runs could have
encountered a satisfying solution early, biasing the results, whereas a “no” instance must
exhaust the entire search tree.) Every graph was sequentially kernelized. As expected, no
bottleneck was encountered during this process. Branching was performed sequentially
and, when sequential times were sizable, in parallel. For standard comparisons, all
parallel runs were timed on 24 cores.

Physical Infrastructure Graphs

We were able to obtain large-scale connectivity information on road systems, airport
networks and power grids. The Road Graph comes to us from California. Its vertices
denote intersections and destinations. Its edges represent connections between these sites.
The Airport Graph is based on direct flight connectivity in the United States. The Power
Graph was obtained from the high voltage power grid for the western states. All three sets
of data were obtained from the Stanford Large Network Dataset Collection.

Both the Road Graph and the Airport Graph produce very small kernels, which complete
branching in under a hundredth of a second. The Power Graph was solved completely
through kernelization, requiring no branching whatsoever. We note that our physical
infrastructure graphs have modest clique sizes and low average degree, and many of their
cliques are disjoint. Therefore, the high degree rule applies to many vertices in their
complements. The graphs are rapidly decomposed almost entirely. This sort of
algorithmic behavior highlights the power of kernelization, and eliminates the need for
heavyweight computations during branching. See Table 7.
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Table 7. Computational experience with large physical infrastructure graphs. Run times
are reported in seconds. The graph derived from power networks was solved completely
during kernelization, and thus needed no branching at all.
Graph

Road

Airport

Power

|V|

30000

1858

4941

|E|

87628

17215

6594

Density

0.00019

0.00998

0.00054

Kernel Size

147

126

7

Clique Size

3

56

6

Sequential Branching

0.00363

0.00598

unneeded

Social Interaction Graphs

We obtained interaction graphs to cover three more or less unrelated social areas. The
Enron Graph represents emails during the company’s financial crisis. The arXiv Graph
denotes a collaboration network, mainly for high-energy physics, whose edges link
electrical preprint co-authorship. Finally, the Wiki-Vote Graph depicts votes for
Wikipedia moderators. As before, all three sets of data were obtained from the Stanford
collection.

As with the physical infrastructure graphs, social graphs kernelize so well that they can
be solved easily by branching sequentially. There is no need for parallelism. In fact, the
arXiv graph was solved completely through kernelization alone. It seems that low
average degree again leads to a very effective application of the high degree rule in the
complement. See Table 8.
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Table 8. Computational experience with large social interaction graphs. Run times are
reported in seconds. The graph derived from electronic preprints was solved completely
during kernelization, and thus needed no branching at all.
Graph

Enron

arXiv

Wiki-Vote

|V|

36692

12008

7115

|E|

183831

118521

100656

Density

0.00027

0.00164

0.00398

Kernel Size

2276

240

2226

Clique Size

20

239

17

Sequential Branching

118.3

unneeded

111.1

High-Throughput Biological Graphs

We tried to focus on markedly different sorts of biological graphs, and ended up
employing data about human proteomics, methylation and transcriptomics. PPI was
created from a curated protein-protein interaction database. Colitis.98 was created using
genomic methylation data from a study on Ulcerative Colitis while LRMS.8 was created
from gene expression microarray data concerning Low-Risk Myelodysplastic Syndrome.
Both data sets are publicly available on the Gene Expression Omnibus (GEO). The
associated datasets are GSE27899 and GSE41130 respectively. For Colitis.98 a weighted
graph was first created using methylation sites as vertices with edges weighted by pvalues of the Pearson correlation between the methylation levels. The same was done for
LRMS.8 using genes and gene expression levels. In each case, the graph was then
converted to an unweighted graph by removing all edges whose weights fall below a
certain threshold (p = .98 and p = .8 respectively).
As with our physical infrastructure and social interaction experiences, kernelization
nearly solved PPI. The other two graphs, Colitis.98 and LRMS.8, were each left with a
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fairly formidable kernel. Although effective parallel vertex cover algorithms have been
tailored to such graphs in previous work [134, 135], it is notable here that, like in the
cases of the Enron and Wiki-Vote graphs, the kernels produced were such that sequential
branching finished in a matter of a very few minutes without the need for parallelism. See
Table 9.

Pseudo-Random Graphs

We created a pair of pseudo-random graphs using standard random graph models, the
Erdös-Rényi model [136] and the Watts-Strogatz model [137]. The Erdös-Rényi graph,
ER_5k, was constructed using an edge density of 0.1. Each potential edge was either
present or absent based on this probability. The Watts-Strogatz graph, WS_800, began
with a regular ring lattice, where every vertex had degree 300. One endpoint of each edge
was then randomly rewired with probability 0.2. We tried to use the Barabási-Albert
preferential attachment model [138] for a third pseudo-random graph. Unfortunately, this
simple model never yields a clique of size greater than x+1, where x is the number of
edges connecting each new node to the existing graph. For instance, when x=2, we obtain
a graph with a maximum clique of size 3. Such graphs and their complements are solved
very quickly by standard clique and vertex cover implementations. We therefore chose to
create the graph Norm_900 by choosing normally distributed random degrees for the
vertices and then setting edges with uniform probability.
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Table 9. Computational experience with large high-throughput biological graphs. Run
times are reported in seconds.
Graph

PPI

Colitis.98

LRMS.8

|V|

9314

12755

14977

|E|

39473

107205

178377

Density

0.00091

0.00132

0.00159

Kernel Size

344

2040

1795

Clique Size

13

19

30

Sequential Branching

0.75154

264.87

229.99

The structure of these pseudo-random graphs seems to be such that some reasonable
modicum of speedup is possible with our balanced tree search. In the case of ER_5k,
speedup seems to have been limited by its low density. Both the Erdös-Rényi and the
Watts-Strogatz models produce graphs whose degree distribution is roughly normal, with
mean centered at the average degree of the graph. We will say more about this issue in
the next section. See Table 10.

Regularly Structured Graphs

We loosely define regularly structured graphs to be those with a narrow degree range.
The limiting case is of course truly regular graphs, whose vertices all have the same
degree. In fact two of the graphs we tested, 5x50_C and 90_Cycle_C, are truly regular.
The third, a subgraph of a Hamming graph, is highly but not truly regular, with vertex
degrees in the range [247,270]. 5x50_C is the complement of the graph obtained by
arranging 50 5-cliques in a circle and connecting the corresponding adjacent clique
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Table 10. Computational experience with large pseudo-random graphs. Run times are
reported in seconds.
Graph

ER_5k

WS_800

Norm_900

|V|

5000

800

900

|E|

1250505

120000

158221

Density

0.10006

0.37547

0.39110

Kernel Size

5000

800

900

Clique Size

7

26

20

7635

8894.45

13027.7

4260

646.5

844.9

Sequential
Branching
Parallel Branching

vertices. 90_Cycle_C was constructed by starting with an even cycle, connecting its
opposite vertices, then taking its complement. That is, beginning with a cycle of length n,
with vertices labeled 0,1,2,...,n-1, add edges (0,n/2), (1, n/2 + 1), (2, n/2 + 2), ... , (n/2-1,
n-1). Figure 24 illustrates this notion with an example for n = 10.

Ham_9_4 was obtained as a 350-node subgraph of a standard Hamming graph,
constructed using parameters n=9 and d=4. In such a graph, vertices are viewed as binary
vectors of length n, and an edge is present if and only if the Hamming distance between
the two vectors is greater than or equal to d.

Because low and high degree vertices are absent, regularly structured graphs are
notoriously difficult, and generally show no benefit whatsoever from kernelization.
Moreover, such graphs tend to have topological symmetry and fill many branches of the
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Figure 24. A regularly structured graph. 90_Cycle_C is the complement of this graph of
order 90.

search tree with near-optimal solutions. Thus, many branches must be fully explored.
Ironically, however, the very topological symmetry that makes such instances difficult
makes them amenable to parallelization. In this study, regularly structured graphs
produced the best speedup we see.

We emphasize that this efficiency is relative. These are not linear-time systolic problems
that easily yield linear speedups. Instead, these are NP-compete problems. Their kernels
require exhaustive search. They generally incur several penalties with respect to
communication overhead, non-uniform memory access and so forth. Thus, we must
temper our enthusiasm and lower our expectations. Nevertheless, the efficiencies we see
are respectable for problems of this ilk. See Table 11.
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Table 11. Computational experience with large regularly structured graphs. Run times are
reported in seconds.
Graph

5x50_C

90_Cycle_C

Ham_9_4

|V|

250

180

350

|E|

6500

15390

44842

Density

0.75155

0.95531

0.73421

Kernel Size

250

180

350

Clique Size

5

90

18

Sequential Branching

369

3802

15686

Parallel Branching

23.75

236

1011.1

Parallel Utilization
There seem to be at least two major factors influencing the relative effectiveness of our
parallel branching strategy: average vertex degree and vertex degree distribution. If the
average vertex degree in the complement is very high, then each time a vertex is added to
a possible cover in a left branch, its many neighbors will be added to a possible cover in
the right branch. This may result in a highly unbalanced search tree, and thus poor
parallel speedup. In Table 4, for example, we see that the density of ER_5k is 0.10006.
Therefore the average degree in its complement is very high, and we witnessed only a
modest speedup. In order to produce a balanced search tree without excessive load
balancing, it seems from these experiments that the complement must exhibit a relatively
tight vertex degree distribution about the mean, with the mean itself relatively low. This
is precisely the case with the regularly structured graphs and with Norm_900.
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We also note that graph size will naturally limit the scalability we can expect to see. On
Ham_9_4, for example, we saw speedups up to 48 cores that then leveled out quickly. On
the other hand, we were able to scale up to 720 cores before leveling out on the larger
Norm_900 graph. See Figures 25 and 26.

Summary
We have studied the significance of kernelization versus branching when solving the
classic vertex cover decision problem on large graphs from five different application
domains. For some, we found that kernelization alone sufficed. For others, we found that
kernelization and branching could work together to find solutions quickly. And yet for
others, we discovered that kernelization fails completely, leaving branching to solve the
entire problem.

An important hallmark of problems amenable to kernelization appears to be a
complement whose degree structure follows an inverse power law distribution. Such a
graph may benefit from reductions by the high degree rule, while its compute kernel may
have a similar distribution, which in turn increases the effectiveness of interleaving. Our
physical infrastructure, social communication, and high throughput biological graphs all
have this type of structure. See, for example, Figure 27. On the other hand, graphs that do
not kernelize were either pseudo-regular or those whose complements’ degree
distributions clustered tightly about a mean value low enough to avoid the high degree
rule. See Figure 28.

Turning now to branching, graphs benefiting most from our parallel strategy were those
that had a relatively tight vertex degree distribution about a relatively low mean. It
remains to be seen whether different branching strategies will behave in markedly
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Ham_9_4
140
120

Speedup
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80
Observed

60

Linear

40
20
0
0

50
100
Number of Processors

150

Figure 25. Speedup for Ham_9_4. Relatively small graph size limits scalability.

Norm_900
1400
1200
Speedup

1000
800
600

Observed

400

Linear

200
0
0

500
1000
Number of Processors

1500

Figure 26. Speedup for Norm_900. Larger graphs provide enhanced opportunities for
scalability.
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Figure 27. Degree distribution of Enron’s complement. Kernelization and sequential
branching proved most effective on graphs whose complements show an inverse power
law degree distribution.

Figure 28. Degree distribution of ER_5k. A normalesque distribution combined with a
sufficiently low mean reduces the benefits of kernelization.
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different ways. In previous work, it has been shown that parallel vertex cover can be
tailored to transcriptomic and other specific classes of graphs [128, 130, 135]. For a given
branching strategy, it might prove fruitful to trace through numerous search trees in an
attempt to identify cases for which the strategy is ideal and those for which it fails.
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CHAPTER FIVE CONCLUSIONS AND DIRECTIONS FOR
FURTHER RESEARCH

We have examined both the application and efficiency of graph-theoretical algorithms to
the study of complex networks. We considered the use of exact solvers for two NPcomplete problems, primarily dominating set and clique, and their utility in solving
difficult biological problems. This work required novel approaches to algorithm
development, as well as implementation and testing on a wide variety of publicly
available data. We also detailed our efforts to analyze the interplay between the two
critical components of fixed parameter tractable implementations. In this final section, we
review the primary contributions of this dissertation and avenues for further research.

Summary of Contributions
The effort has focused on the development of combinatorial tools for the analysis of
complex networks. Its primary contributions are the adaptation of a graph-based
toolchain for biomarker discovery to DNA methylation data, with improvements to the
method, a novel method for identifying subtypes of complex disease from gene
expression data using the paraclique algorithm, and an empirical study of the relative
significance of kernelization compared to branching on different graph classes for the
vertex cover problem on parallel platforms. Although the application focus in the
development of these algorithms was mainly on microbiology, their foundation is set in
the mathematical abstraction of graph theory. As such, their applications transfer easily to
other domains. Together, these results provide algorithmic advances for the study of
complex networks as well as insight into the design of efficient algorithms through the
use of fixed parameter tractability.
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Originally, the graph-based toolchain for biomarker discovery was designed for gene
expression data. Our contributions expanded and improved it in several key ways:
•

Its adaptation to methylation data required scaling to a ten-fold increase in the
number of variables.

•

We introduced a tuning factor to address initial runs not identifying sites with
positive merit scores.

•

We employed an exact rather than an approximate dominating set filter.

•

We added a neural net classifier to the toolchain.

We then tested the improved method on eight data sets obtained from GEO representing a
variety of complex human disease. With the exception of chronic fatigue associated with
Sjogren’s syndrome, our method performed well in all cases. For instance, in breast
cancer data, it identified a set of only five methylation sites that the neural net classifier
used to discriminate between tumor and healthy tissue samples with an accuracy of 0.96.
We note that our method is of course reliant on the data provided. Methylation
biomarkers may be observable in one type of tissue, but not others. For example, the
inability to identify markers in the Sjogren’s syndrome data may indicate the absence of a
link between associated chronic fatigue and methylation levels, or only that such markers
are not carried in peripheral blood.

The method we developed for using the paraclique algorithm to identify putative
subgroups in gene expression data has several key features:
•

It reduces the effects of confounding factors by introducing an initial filtering
step when accompanying control data is available.

•

It transposes the correlation matrices typically used in a gene network analysis,
computing sample-sample correlations to which a threshold is applied to build a
graph.

•

It then applies the paraclique algorithm to identify dense subgraphs representing
potential subtypes.
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We applied the method to twelve publicly available data sets obtained from GEO
representing a range of human disease. Our method identified putative subtypes in ten of
those cases. In the other two cases, we feel that either there is no discernable molecular
subtype associated with the disease, or perhaps more likely, the available data set was too
small to allow its discovery. To help validate the putative subtypes produced by our
method, we conducted a literature review for the involvement of genes differentially
expressed between paracliques having known biological relevance. We also conducted
GO enrichment to determine whether the method differentiated between known
molecular subtypes. Despite our efforts at validation, we recognize that this work is
somewhat limited by a lack of ground truth. Further investigation into the biological role
of the genes driving the separation of our putative subtypes is needed.

To investigate the relative significance of kernelization compared to branching in a
parallel FPT version of a vertex cover solver, we implemented several reduction rules,
including the low degree, high degree and full degree rules. We performed extensive
testing on a variety of large graphs with different structural characteristics drawn from
five classes. The tests were ran on the Hopper machine at the NERSC facility, at the time
the 16th fastest supercomputer for academic research in the world. Our testing revealed
wide disparities between classes of graphs. Graphs whose degree structure follow a
power law or inverse power law distribution can be almost completely solved with
kernelization, while pseudo-regular graphs gain little benefit from kernelization, and must
rely entirely on branching. The parallel speedup obtained by our algorithm relies greatly
on the structure of the input graph. Potential steps to reduce this dependence and improve
scalability include investigating alternative branching strategies and improving load
balancing.
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Possible New Directions for Future Work
The work presented in this dissertation represents a stepping stone in the path to
harnessing the power of exact solutions to NP-complete graph problems for the practical
exploration of large, complex networks. As such, it leaves open a variety of avenues for
further research.

The work on methylation biomarker discovery could potentially form the basis for the
analysis of other types of epigenetic data. Given the success of using our dominating set
filter for feature selection, future work is warranted to investigate potential synergies
between classical graph algorithms and traditional machine learning approaches.
Additionally, work remains to be done improving the current state of the art
implementations of dominating set.

The subtyping work can also be applied to other types of data rather than gene
expression, such as epigenetic data. In particular, it would be interesting to see how well
the approach adapts to categorical data. An open area is the development of automatic
validation metrics to judge the “goodness” of putative subtypes.

Finally, the work on FPT vertex cover in chapter four opens several paths forward.
Perhaps most promising would be the development of structural metrics that predict
scalability and performance of various vertex cover/clique finders. With such metrics in
hand, one could then design a targeted solver that would select the best approach based
on the input graph. As we observed, satisfactory parallel speedup in our current
implementation often depends on the structure of the input graph. As such, much work
remains in developing parallel graph algorithms for problems such as vertex cover that
require highly randomized memory access.
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